How AI Can Unlock Personalized Cancer Care

What does truly personalized cancer care actually look like in the years ahead? 

In this clip from our episode “When AI Spots What Doctors Miss”, HealthBiz Podcast host David Williams speaks with Steve Brown, Founder and CEO of CureWise, about how AI and full-genome sequencing could enable truly individualized cancer treatment. 

Listen to the full episode here

🎙️⚕️ABOUT STEVE BROWN
Tech innovator and AI expert with a passion for creating impactful solutions. As a developer, he's built numerous apps and led two startups to successful acquisitions by global companies. As a filmmaker, his award-winning documentaries have been featured in theaters and on major networks. Driven by the power of media and technology to transform relationships and make a lasting impact.

🎙️⚕️ABOUT HEALTH BIZ PODCAST
HealthBiz is a CareTalk podcast that delivers in-depth interviews on healthcare business, technology, and policy with entrepreneurs and CEOs. Host David E. Williams — president of the healthcare strategy consulting boutique Health Business Group — is also a board member, investor in private healthcare companies, and author of the Health Business Blog. Known for his strategic insights and sharp humor, David offers a refreshing break from the usual healthcare industry BS.

GET IN TOUCH
Follow CareTalk on LinkedIn
Become a CareTalk sponsor
Guest appearance requests
Visit us on the web
Subscribe to the CareTalk Newsletter

Transcript

David: 0:07

So things are moving very quickly as you, uh, described, but not only is, you know, medical knowledge has also has grown a lot, but AI is moving quickly and the, the brain doesn't understand exponential growth too well and can't relate to it. So, but where do you see things going over the next few years? I mean, if we have this conversation in three to five years, what is AI powered? Diagnosis and treatment planning gonna look like at that point.

Steve: 0:32

It's really getting to truly personalized medicine, um, and precision medicine. So I mentioned earlier on that, you know, if a million people have cancer, it's a million different genetically unique diseases. Yeah. Point. Every one of those people is gonna get their own precis, precision optimized cocktail that's, that's optimized for whatever their unique condition is. How do we get there? Um, and right now we're looking for fragments of DNA and fragments of, uh, genes in the. In the, you know, the soup related to your, to your cancer. Yeah. And that's, you know, fairly incomplete. But we're gonna be sequencing the entire genome of those cancer cells, and then we're gonna be using AI to predict the evolution. Because, you know, if you, if you, let's say we discover this weakness in your. Cancer. Hey, it's keeping itself alive because of this particular weakness. Let's treat that. Well. Chances are it's gonna evolve a workaround. Yeah. But you, if you understand what that weakness is and how it might try to evolve a workaround, maybe you'll hit the workarounds at the same time in a better cocktail. And you'll knock it out, um, you know, uh, with a higher probability and, and, and faster. So there's a lot that's gonna happen because we actually know more about the cancer. Cancer is really unique, uh, disease because it's your own cells. That have decided, hey, I'm not part of the whole anymore. Yeah. I'm gonna evolve on my own and do my own thing. And it becomes a parasite. Um, and it, but it's evolving. It's its own kind of, uh, you know, like, uh, Darwinian, uh, yeah, that's going on. So it's. You kind of have to crack the code on life itself to really figure out cancer, which is why it's kind of interesting to, to, to dive in because as we figure that out, we're gonna figure out a lot of other things. Um, it's gonna have a massive impact on, on, on healthcare in general, but this is like becoming the most expensive disease we have. Yeah. Uh, and it's the frontier. Of all of this new, um, kind of new field of, uh, diagnostic diagnostics and all the new molecules and things we're discovering, you know, also with ai. So, you know, it's like three exponentials converging. Yeah, the exponentials on the, the genomics and molecular profiling, the, the exponentials and all the new ideas for, um, uh, molecules that might work, and the exponential of ai. So these things are converging in a way that I think it's, there's really a shot at getting closer and closer to what, what we call cures.